Lead compounds

ImmuPharma has five lead drug candidates in development, each of which targets a niche market and addresses a serious medical condition. Each of them also has potentially significant sales, lower entry marketing costs and a relatively low risk of drug development failure.

Treatment for Lupus (Lupuzor ^TM)

Lupus is a chronic, potentially life-threatening autoimmune disease. An estimated one million people in the seven major markets have been diagnosed with this inflammatory disease which attacks multiple organs such as the skin, joints, kidneys, blood cells, heart and lungs. There is currently no cure or specific treatment. Lupuzor ^TM has a novel mechanism of action aimed at modulating the body’s immune system so it does not attack healthy cells without causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.

Treatment for cancer (IPP-204106)

IPP-204106, has a dual mechanism of action, acting both in preventing angiogenesis as well as proliferation. IPP-204106 is a nucleolin antagonist, the lead molecule in a family of pseudopeptides designed to block the activity of a protein called nucleolin. Located essentially in the nucleus of normal cells where it is protected, nucleolin is much more abundant (often 30 times more) at the surface of the cells which are proliferating as well as the surface of active endothelial cells where it can be a target for antagonist peptides.

Relief from severe cancer and post-operative pain (IPP-102199)

ImmuPharma is developing a potential non-addictive compound for relieving moderate to severe pain, such as experienced by cancer sufferers and post-surgical patients. Most existing treatments are derived from the opiate morphine and tend to have serious side effects. ImmuPharma's new treatment is based on met-enkephalin, the body's internal analgesic. IPP-102199 is being developed to have major advantages over morphine such as longer pain relief duration and reduced side effects. The market for chronic opioids in the US currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a year.

Treatment for highly resistant, hospital-acquired infections, such as MRSA (IPP-203101)

This is a novel antibiotic to combat MRSA and other severe hospital-acquired, resistant infections which affect some two million people in the US, according to the US Centers for Disease Control and Prevention. ImmuPharma's drug candidate is targeted at disrupting the membrane potential of the bacterial pathogens. It is hoped this novel approach will reduce their potential to become resistant.

Treatment for inflammatory and allergic disorders (IPP-201007)

Discovered from ImmuPharma's library of compounds, this is a Phospholipase A2 (PLA2) inhibitor chemical series with the potential to reduce allergic reactions and inflammatory conditions.

click the compound number for more information


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	Lead compounds ImmuPharma has five lead drug candidates in development, each of which targets a niche market and addresses a serious medical condition. Each of them also has potentially significant sales, lower entry marketing costs and a relatively low risk of drug development failure. Treatment for Lupus (Lupuzor ^TM) Lupus is a chronic, potentially life-threatening autoimmune disease. An estimated one million people in the seven major markets have been diagnosed with this inflammatory disease which attacks multiple organs such as the skin, joints, kidneys, blood cells, heart and lungs. There is currently no cure or specific treatment. Lupuzor ^TM has a novel mechanism of action aimed at modulating the body’s immune system so it does not attack healthy cells without causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients. Treatment for cancer (IPP-204106) IPP-204106, has a dual mechanism of action, acting both in preventing angiogenesis as well as proliferation. IPP-204106 is a nucleolin antagonist, the lead molecule in a family of pseudopeptides designed to block the activity of a protein called nucleolin. Located essentially in the nucleus of normal cells where it is protected, nucleolin is much more abundant (often 30 times more) at the surface of the cells which are proliferating as well as the surface of active endothelial cells where it can be a target for antagonist peptides. Relief from severe cancer and post-operative pain (IPP-102199) ImmuPharma is developing a potential non-addictive compound for relieving moderate to severe pain, such as experienced by cancer sufferers and post-surgical patients. Most existing treatments are derived from the opiate morphine and tend to have serious side effects. ImmuPharma's new treatment is based on met-enkephalin, the body's internal analgesic. IPP-102199 is being developed to have major advantages over morphine such as longer pain relief duration and reduced side effects. The market for chronic opioids in the US currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a year. Treatment for highly resistant, hospital-acquired infections, such as MRSA (IPP-203101) This is a novel antibiotic to combat MRSA and other severe hospital-acquired, resistant infections which affect some two million people in the US, according to the US Centers for Disease Control and Prevention. ImmuPharma's drug candidate is targeted at disrupting the membrane potential of the bacterial pathogens. It is hoped this novel approach will reduce their potential to become resistant. Treatment for inflammatory and allergic disorders (IPP-201007) Discovered from ImmuPharma's library of compounds, this is a Phospholipase A2 (PLA2) inhibitor chemical series with the potential to reduce allergic reactions and inflammatory conditions. click the compound number for more information